Paul Matteis

Latest articles

30d
Market Watch
Alnylam shares surge 40% on drug results that may herald a new type of medicinedrug’s development earlier this month and was forced to discontinue another dru
Market Watch / Posted 30 days ago
drug’s development earlier this month and was forced to discontinue another drug last fall, said Leerink Partners analyst Paul Matteis. The results also appear to be a best-case scenario for the company, he said, noting that the safety data... Read more
m
Market Watch
Nabriva Therapeutics’ latest good news soothes concerns about chief medical officer’s departurethe resignation just ahead of the data,” especially given how detailed Monday’s
Market Watch / Posted 1 months ago
the resignation just ahead of the data,” especially given how detailed Monday’s release was, said Leerink Partners analyst Paul Matteis. The latest clinical trial results found that the drug is about as effective as the current gold standard... Read more

In this news